on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Enhances Polymer Testing for PNKP Inhibitor Development
Onco-Innovations Limited, based in Vancouver, has announced progress in its analytical methods for its PNKP Inhibitor Technology. The company has advanced the measurement of a critical polymer, crucial for its nanoparticle micelle delivery system. This development supports formulation and scale-up, vital as the company prepares for IND-enabling studies.
Utilizing refractive index detection with gel permeation chromatography (RI-GPC), Onco can assess polymer molecular weight and distribution, ensuring batch consistency. This analytical control aims to enhance formulation reproducibility, manufacturing scale-up, and reduce development risks ahead of regulatory and clinical stages.
RI-GPC is a standard tool for evaluating polymer quality, affecting nanoparticle behavior and scalability for clinical use. Strengthening this control fortifies the company's Chemistry, Manufacturing, and Controls package in preparation for regulatory review.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news